- CA$157.84m
- CA$248.15m
- $63.07m
- 54
- 65
- 43
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.17 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 7.36 | ||
| Price to Sales | 1.82 | ||
| EV to EBITDA | 12.97 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.25% | ||
| Return on Equity | -24.69% | ||
| Operating Margin | -44.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 54.16 | 56.11 | 60.01 | 61.47 | 63.07 | 64.02 | 73.64 | 0.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Directors
- William Wells CHM (60)
- Gilbert Godin CEO (62)
- Tim Hendrickson CFO (49)
- Norma Beauchamp CEX (60)
- Jason Gross VPR (56)
- Ryan Lennox GCN (40)
- John Welborn MDR (44)
- David Spence CTR (53)
- Sanjiv Sharma OTH (65)
- Hemanth Varghese OTH (45)
- J. Spencer Lanthier LED (80)
- Yvon Bastien IND (73)
- Laura Brege IND (63)
- Donald Degolyer IND (59)
- Greg Gubitz IND (63)
- Rodney Hill IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 12th, 2018
- Public Since
- March 17th, 1980
- No. of Employees
- 91
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 31,886,247
- Address
- 10 Carlson Court, Suite 701, ETOBICOKE, M9W 6L2
- Web
- https://www.hlstherapeutics.com/
- Phone
- +1 6474959000
- Contact
- Dave Mason
- Auditors
- Ernst & Young LLP
Upcoming Events for HLS
HLS Therapeutics Inc Annual Shareholders Meeting
Q2 2024 HLS Therapeutics Inc Earnings Release
Similar to HLS
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
What is the HLS Therapeutics share price?
As of Today at 19:10 UTC, shares in HLS Therapeutics are trading at CA$4.95. This share price information is delayed by 15 minutes.
How has the HLS Therapeutics share price performed this year?
Shares in HLS Therapeutics last closed at CA$4.95 and the price had moved by -17.5% over the past 365 days. In terms of relative price strength the HLS Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -21.72% over the past year.
What are the analyst and broker recommendations for HLS Therapeutics?
The overall consensus recommendation for HLS Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the HLS Therapeutics dividend yield?
HLS Therapeutics does not currently pay a dividend.
Does HLS Therapeutics pay a dividend?
HLS Therapeutics does not currently pay a dividend.
When does HLS Therapeutics next pay dividends?
HLS Therapeutics does not currently pay a dividend.
How do I buy HLS Therapeutics shares?
To buy shares in HLS Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of HLS Therapeutics?
As of the previous close price of CA$4.95, shares in HLS Therapeutics had a market capitalisation of CA$157.84m.
Where are HLS Therapeutics shares listed?
Here are the trading details for HLS Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: HLS
What kind of share is HLS Therapeutics?
Based on an overall assessment of its quality, value and momentum HLS Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a HLS Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in HLS Therapeutics is CA$6.73. That is 35.98% above the last closing price of CA$4.95.
Analysts covering HLS Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
What is the trend in the HLS Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HLS Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -13.71%.
As of the last closing price of CA$4.95, shares in HLS Therapeutics were trading +5.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the HLS Therapeutics PE Ratio?
The HLS Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$4.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of HLS Therapeutics?
HLS Therapeutics' management team is headed by:
- William Wells - CHM
- Gilbert Godin - CEO
- Tim Hendrickson - CFO
- Norma Beauchamp - CEX
- Jason Gross - VPR
- Ryan Lennox - GCN
- John Welborn - MDR
- David Spence - CTR
- Sanjiv Sharma - OTH
- Hemanth Varghese - OTH
- J. Spencer Lanthier - LED
- Yvon Bastien - IND
- Laura Brege - IND
- Donald Degolyer - IND
- Greg Gubitz - IND
- Rodney Hill - IND